Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. š“ Alkermesā narcolepsy drug succeeds in Phase 3 study: The companyās drug Lumryz, approved in 2023 for narcolepsy, hit its primary ...
May 12, 2026 09:37 AM EDT News Briefing AlkĀerĀmes' narĀcolepĀsy Phase 3 sucĀcess; Boehringer's anĀtiĀbody deal ENDPOINTS Plus, news from VistaĀgen, EnĀterĀprise TherĀaĀpeuĀtics, CereĀvance and MeĀmenĀto MedĀiĀcines. š“ AlkĀerĀmesā narĀcolepĀsy drug sucĀceeds in Phase 3 study: The comĀpaĀnyās drug LumĀryz, apĀproved in ā¦ Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window Ā· permanent after that